Ruxandra Gref

Title: Ruxandra Gref and a β-Cyclodextrin-Based Approach to Tuberculosis Treatment.

Introduction

Ruxandra Gref is an inventor based in Orsay, France, whose work explores materials that may support improved treatments for tuberculosis. Her research focuses on cross-linked poly-β-cyclodextrin (pβCD) nanoparticles, which have been investigated both as carriers for anti-tuberculosis drugs and for their own antibacterial effects.

Latest Patents

Gref is associated with 1 patent: “Use of materials made of cross-linked β-cyclodextrins for the treatment of tuberculosis.” The patent describes research into multidrug-resistant tuberculosis, a serious public health challenge, and the difficulties patients face with lengthy treatment regimens.

The reported findings suggest that pβCD nanoparticles can carry combinations of anti-tuberculosis drugs for pulmonary delivery. The research also indicates that empty pβCD nanoparticles may hinder the establishment of *Mycobacterium tuberculosis* in mice and interfere with the colonization of macrophages, without inducing toxicity. The proposed effects include disrupting lipid rafts and promoting apoptosis in infected macrophages, potentially creating lung conditions less favorable to bacterial persistence.

Career Highlights

Gref’s work connects materials science and drug-delivery research with the search for more effective tuberculosis treatments. The patent presents cross-linked β-cyclodextrin materials as potential components of treatment formulations, whether used alone or loaded with antibiotics.

Collaborations

The supplied career information associates Gref with Université de Lille and the French National Institute of Health and Medical Research (INSERM). Her listed coworkers include Alain Boulard and Arnaud Machelart.

Conclusion

Ruxandra Gref’s patent highlights the potential of cross-linked β-cyclodextrin materials to serve both as drug carriers and as materials with antibacterial activity, offering a research direction for improved tuberculosis treatment formulations.